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Age, JAK2V617F and SF3B1 mutations are the main predicting
factors for survival in refractory anaemia with ring sideroblasts
and marked thrombocytosis
J Brose´us1, T Alpermann2, M Wulfert3, L Florensa Brichs4,10, S Jeromin2, E Lippert5, M Rozman6,10, F Lifermann7, V Grossmann2,
T Haferlach2, U Germing3, E Lun˜o8,10, F Girodon9 and S Schnittger2 for the MPN and MPNr-EuroNet (COST Action BM0902)
Refractory anaemia with ring sideroblasts (RARS) and marked thrombocytosis (RARS-T) is a provisional entity in the World Health
Organisation 2008 classiﬁcation and has previously been shown to have a high proportion of JAK2V617F (Janus Kinase 2) and SF3B1
(Splicing Factor 3B subunit 1) mutations. The purpose of the present study was to analyse the frequency of SF3B1 mutations in a
large cohort of 111 patients with RARS-T and 33 patients with RARS and to explore the prognostic impact of SF3B1 mutational
status on RARS-T. The frequency of SF3B1 mutations in RARS-T (96/111, 86.5%) and RARS (28/33, 84.8%) was similar. In RARS-T,
median survival was better in SF3B1-mutated patients than in SF3B1-non-mutated patients (6.9 and 3.3 years, respectively,
P¼ 0.003). RARS can be differentiated from RARS-T by the frequency of JAK2V617F (0% vs 48.6%). In RARS-T patients, SF3B1
(P¼ 0.021) and JAK2 mutations (P¼ 0.016) were independent factors for a better prognosis. Altogether, our results conﬁrm that
RARS-T is an independent entity that should be recognised by the next World Health Organisation classiﬁcation. The assessment of
SF3B1 mutations is of prognostic interest in RARS-T patients. Younger age, JAK2V617F and SF3B1 mutations are the main predicting
factors for survival in RARS-T.
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INTRODUCTION
Refractory anaemia with ring sideroblasts (RARS) and marked
thrombocytosis (RARS-T) has been proposed in the World Health
Organisation 2001 classiﬁcation of tumours of haematopoietic
and lymphoid tissues and retained as a provisional entity in the
classiﬁcation of 2008.1 RARS-T is classiﬁed in the myelodysplastic/
myeloproliferative (MDS/MPN) disorders group, because it
presents with the dysplastic features of RARS2 and the
myeloproliferative features of essential thrombocythemia (ET).3
RARS-T is characterised by a high rate of JAK2V617F (Janus Kinase 2)
mutations4–15 and/or the presence of the mutation MPLW515L/R
(MyeloProliferative Leukemia).16,17 The classiﬁcation of RARS-T as an
entity that is independent from RARS or ET is currently a matter of
debate. Several specialists favour the hypothesis that RARS-T is a
form of ET with Z15% of ring sideroblasts in the bone marrow18
while others think that RARS-T develops from RARS with
secondary thrombocytosis accompanying the acquisition of the
JAK2V617F mutation.19
Recent publication from our group in a European retrospective
multicentre collaborative study demonstrated that RARS-T was
independent from RARS and ET from a clinical and biological as
well as prognostic point of view.20
Our results have recently been strengthened by the discovery of
the association between myelodysplastic syndromes and muta-
tions involving components of the RNA splicing machinery,
including U2AF35 (U2 small nuclear RNA Auxiliary Factor 35), ZRSR2
(Zinc ﬁnger CCCH type, RNA-binding motif and Serine/aRginine
rich 2), SRSF2 (Serine/aRginine-rich Splicing Factor 2) and SF3B1
(Splicing Factor 3B subunit 1). SF3B1mutations (SF3B1mut) are found
in about 20% of total MDS and correlate strongly with the
presence of Z15% of ring sideroblasts (MDS-RS; 64–82.6% in
RARS, 57–76% in refractory cytopenia with multilineage dysplasia
and ring sideroblasts (RCMD-RS) and 66.7–72% in RARS-T).21–27 On
the other hand, mutations of SF3B1 are found at a lower frequency
in MDS with o15% ring sideroblasts, which conﬁrms the
speciﬁcity of SF3B1mut in MDS-RS. SF3B1 mutations are rare in
myeloproliferative neoplasms and particularly in ET (0–3%).22,28
The high frequency of SF3B1 mutations suggests that these
mutations have a pathophysiological role in these diseases,
probably through perturbations of RNA splicing. The link
between SF3B1-mutated status and ring sideroblasts has been
conﬁrmed in a recent experimental study on murine models.29
About one quarter of MDS-RS are SF3B1wt and somatic mutations
of SRSF2 or ZRSR2 have been described in about 7% of MDS-RS,21
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which suggests that other mutant genes may have a role in the
appearance of ring sideroblasts. Furthermore, a recent study
showed that RARS-T presented with a particular genetic pattern
with a high frequency of JAK2V617F and SF3B1 mutations,
conﬁrming the classiﬁcation of RARS-T in the category of
myelodysplastic/myeloproliferative neoplasms.30
Finally, as precedent studies have been performed on little
RARS-T cohorts, the prognostic impact of SF3B1mut status remains
controversial,22,24,25,27,31 and there is a need for a study on a larger
cohort. Our purpose was to analyse the frequency of SF3B1
mutations in a large cohort of 111 RARS-T and to explore the
prognostic impact of SF3B1 mutations in this disorder.
PATIENTS AND METHODS
Patient selection
According to the World Health Organisation 2008 classiﬁcation, patients
were diagnosed with RARS-T if they fulﬁlled the following criteria: (i)
anaemia (haemoglobin levelo125 g/l for females ando135 g/l for males)
with erythroid dysplasia andZ15% ring sideroblasts; (ii) thrombocytosis of
Z450 109 platelets/l; (iii) o5% blast cells in the bone marrow; (iv) the
presence of large atypical megakaryocytes similar to those observed in
BCR-ABL1-negative myeloproliferative neoplasms; (v) no secondary cause
of ring sideroblasts; and (vi) no karyotype abnormalities, such as del(5q),
t(3;3)(q21;q26) or inv(3)(q21q26).1
To obtain a comprehensive data set of this rare entity, samples from
seven European centres in three European countries were collected. The
total cohort comprised 111 cases of RARS-T and 33 cases of RARS.
Data record
For each patient, demographic (gender, age at diagnosis, date of death or
last follow-up) and biological data (blood cell count, bone marrow
exploration, ring sideroblasts, karyotype, molecular explorations) were
collected.
The SF3B1 mutations were analysed with a sensitive next-generation
amplicon deep-sequencing assay (454 Life Sciences, Branford, CT, USA)
with a median coverage of 500 reads. This approach was able to detect
mutations with a sensitivity o1%.
The JAK2V617F mutation was analysed by allele-speciﬁc real-time PCR to
estimate allele burden according to methods published by Lippert et al.32
and Schnittger et al.33 with a sensitivity of 1%. JAK2exon12 analysis was
performed according to the method of Schnittger et al.,34 and the MPLW515
mutations were analysed by high-resolution melting curve analyses
followed by Sanger sequencing if positive, as previously published by
Schnittger et al.35
Statistical analyses
Standardised overall survival was estimated by the Kaplan–Meier method
and based on the time from diagnosis to death or last contact. Survival
curves for the different groups were compared using the log rank test.
Multivariate analysis was performed using Cox’s proportional hazards
model.
Approval for the study was obtained from the ethics committee of each
institution, and the procedures were carried out in accordance with the
Helsinki Declaration of 1975, as revised in 2000.
RESULTS
Demographic and biological features
A total of 144 cases (111 RARS-T and 33 RARS including 72 males
and 72 females) were recorded in the study. Median age at
diagnosis was 73.9 years (range: 44.4–96.1 years). The median
follow-up was 37.5 and 55.2 months for the RARS-T and RARS
cohort, respectively (Table 1). Survival data were available in 130
(97 RARS-T and 33 RARS) of the 144 patients.
Frequencies and characterisation of mutations
A karyotype was available in 128 cases. One hundred and ten
(85.9%) patients carried a normal karyotype, whereas 18 (14.1%)
patients showed aberrant karyotypes, which was equally
distributed between RARS-T and RARS patients. Even if the IPSS
(International Prognostic Scoring System) score can only be
applied to MDS de novo, we calculated it to check if we had a
homogeneous group of patients. Most of the patients of the total
cohort (133 out of 144) had an IPSS score of 0.
A SF3B1mut was noted in 124 out of the 144 patients (86.1%).
A total of 127 SF3B1 mutations were detected in these 124
patients (28 RARS and 96 RARS-T). Three RARS-T cases carried two
Table 1. Demographic and biological characteristics of RARS-T and
RARS patients
RARS-T patients RARS patients
n 111 33
Male (%) 46.8 60.6
Age at diagnosis (years)
Median 74.3 71.1
Range 44.4–92.1 48.4–96.1
20–50 years, n (%) 4 (3.6) 2 (6.1)
50–70 years, n (%) 36 (32.5) 9 (27.2)
470 years, n (%) 71 (63.9) 22 (66.7)
Available survival data (n) 97 33
Median follow-up (years) 3.1 4.6
WBC ( 109/l)
Median 7.6 5.2
Range 2.1–60.0 1.6–17.3
Hb (g/l)
Median 96.5 91.0
Range 51.0–131.0 69.0–128.0
Platelets ( 109/l)
Median 646 314
Range 452–1500 61–444
450–600, n (%) 54 (48.6)
4600, n (%) 57 (51.4)
Ring sideroblasts (%)
Median 52 40
Range 16–97 19–85
SF3B1 mutations (%) 86.5 84.8
Tested (n) 111 33
Mutated (n) 96 28
p.Lys700Glu 51 16
p.Lys666Glu/Thr/Asp/Asn 16 2
p.His662Asp/Gln 11 2
p.Glu622Asp 7 2
p.Arg625Gys/Leu/Gly 5 3
p.Thr663Pro 2 2
p.Met784_Lys785delinsIle 1 0
p.Asp781Gly 0 1
Two different mutations 3 0
JAK2V617F mutations (%) 48.6 0
Tested (n) 111 33
MPL mutations (%) 1 0
Tested (n) 102 27
IPSS
0 104 29
0.5 5 3
1 2 1
Abbreviations: Hb, haemoglobin; IPSS, International Prognostic Scoring
System; JAK2, Janus Kinase 2; MPL, MyeloProliferative Leukaemia; RARS,
refractory anaemia with ring sideroblasts; RARS-T, refractory anaemia with
ring sideroblasts and marked thrombocytosis; SF3B1, Splicing Factor 3B
subunit 1; WBC, white blood cells.
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different mutations. With the exception of one p.Arg549Cys in
exon 12 and two in exon 16, all mutations were located in exons
14 and 15. All but one del/ins mutations (p.Met784_Lys785del/
insIle) were missense mutations. In detail, the most frequent
mutation was p.Lys700Glu (68/127 53.5%), followed by p.Lys666-
Glu/Thr/Asp/Asn mutations (n¼ 18, 14.2%), p.His662Asp/Gln
(n¼ 13, 10.2%), p.Arg625Cys/Leu (n¼ 10, 7.9%), p.Glu622Asp
(n¼ 9, 7.1%) and p.Thr663Pro (n¼ 4, 3.1%). Five further mutations
were detected in single cases only. Frequencies and positions of
mutations are illustrated in Table 1 and Figure 1. Median
mutation/wildtype load was 40% (range: 15–78%). Small sub-
clones with SF3B1mut were not detected.
Frequency of mutations in RARS and RARS-T
The frequency of SF3B1 mutations in RARS-T (96/111, 86.5%) was
similar to that in RARS (28/33, 84.8%). By contrast, both entities
differed by the presence of the JAK2V617F mutation, which was
detected in 54/144 (37.5%) in the total cohort but in 54/111
(48.6%) in RARS-T compared with none (0/33) in RARS (Po0.001).
Among the RARS-T SF3B1mut, 46/96 (47.9%) harboured a JAK2V617F
mutation. JAK2V617F allele burden was very heterogeneous with a
median of 49% (range: 1–100%). No JAK2exon12 mutation (111
tested) was observed, whereas only one case with the MPLW515L
mutation was noted in a RARS-T (102 tested; Table 1 and Figure 2).
Biological association
The presence of SF3B1mut was analysed with respect to age, sex,
white blood cell count, haemoglobin levels, platelet counts, blast
counts, percentage of ring sideroblasts, karyotype and JAK2V617F
allele burden. In RARS-T, SF3B1 mutations were more frequent in
females (56/59, 94.9%) than in males (40/52, 76.9%) (P¼ 0.010),
and mean ring sideroblast counts were higher in SF3B1mut than in
SF3B1wt (55% vs 38%) (P¼ 0.007). No further correlations were
detected for these parameters.
Impact of mutations on outcome
The difference in survival between RARS-T and RARS was not
statistically signiﬁcant (median survival 10.7 vs 6.2 years,
respectively, P40.05). On the other hand, in the total cohort,
patients with SF3B1mut had longer survival than those with
Figure 1. Positions and characterisation of mutations in the HEAT domains 1–6 (exons 12–16) of the SF3B1 gene. Missense mutations are
indicated in green and the rare ins/del mutation in yellow. HEAT, Huntingtin, elongation factor 3, protein phosphatase 2A, Tor1; PPP1R8,
protein phosphatase 1, regulatory subunit 8; aa, amino acid.
Figure 2. Distribution of SF3B1, JAK2V617F and MPLW515L mutations in RARS-T and RARS.
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SF3B1wt (8.0 vs 1.8 years, respectively, Po0.001; Figure 3a). When
restricted to RARS-T (85 SF3B1mut and 12 SF3B1wt), median overall
survival was 6.9 years in SF3B1mut vs 3.3 years in SF3B1wt
(P¼ 0.003; Figure 3b). In RARS, survival was 10.7 years in the
SF3B1mut (n¼ 28) and 1.8 years in SF3B1wt patients (n¼ 5;
P¼ 0.001; Figure 3c). In RARS-T patients, the survival rates at 2, 4
and 6 years within the JAK2V617F sub-cohort were 94.9, 84.3 and
67.4%, respectively, while within the JAK2wt sub-cohort, they were
79.7, 69.6 and 32.2%, respectively. JAK2V617F (n¼ 50) was then
associated with a more favourable outcome compared with
JAK2wt (n¼ 47; P¼ 0.019; Figure 3d).
Cox regression analysis
In the total cohort including RARS-T and RARS cases in univariate
analysis, age (P¼ 0.020), ring sideroblast count (P¼ 0.008) and
SF3B1 mutational status (Po0.001) were prognostically signiﬁcant,
but SF3B1 mutational status was the only independent prognostic
factor (P¼ 0.001) in multivariable analysis.
In the RARS-T cohort in univariate analysis, age (P¼ 0.038), ring
sideroblast count (P¼ 0.014), JAK2V617F (P¼ 0.024) and SF3B1mut
(P¼ 0.006) were prognostically signiﬁcant but only age (P¼ 0.044),
JAK2V617F (P¼ 0.016) and SF3B1mut (P¼ 0.021) were independent
prognostic parameters in multivariable analysis. Survival was
better in patients with age r80 years, JAK2V617F and SF3B1
mutations. Taking into account these three prognostic factors, a
model for survival in RARS-T patients was constructed in which
each risk factor (that is, age 480 years, SF3B1wt and JAK2wt) was
worth 1 point and deﬁned two groups of risk: high risk for patients
with a score of 2 or 3 (n¼ 13) and low risk when the score is 0 or 1
(n¼ 84). Median survival in the high-risk group was 1.6 vs 8.0 years
in the low-risk group (Po0.001; corresponding survival rates at 2,
4 and 6 years are 31.4, 31.4 and 0% for high-risk patients vs 95.8,
84.4 and 62.8% for low-risk patients; Figure 4).
DISCUSSION
Up to now, SF3B1 mutations have been studied in small series of
RARS-T patients. In this study, we provide data on SF3B1 mutations
in a large cohort of RARS-T patients, which is, to the best of our
knowledge, the largest published to date.
SF3B1 mutations were observed with a high frequency in both
RARS-T and RARS patients (86.5% and 84.8%, respectively). These
proportions are slightly higher than those already published, as
SF3B1 mutations have been found in 64–82.6% of RARS21–24 and
66.7–72% in RARS-T.23,24 The slightly higher frequency of SF3B1
mutations in the current study may be due to the larger cohort of
RARS-T patients than in other studies. There may also be
differences in methodology, for example, direct sequencing vs
non-sequencing-based screening strategies.
However, RARS differs from RARS-T in that there are no
JAK2V617F mutations in RARS,4,14 whereas there is a high
frequency in RARS-T.4–13,15,19 We recently showed that RARS-T
differed from RARS and ET from a clinical, biological and
SF3B1mut
(n=113, median 8.0 yrs)
p<0.001
SF3B1wt
(n=17, median 1.8 yrs)
12451117
10101214202845567588113
Patients at risk
1123712
668912153141566685
Patients at risk
SF3B1mut
(n=85, median 6.9 yrs)
SF3B1wt
(n=12, median 3.3 yrs)
p=0.003
12245
44458131415192228
Patients at risk
SF3B1mut
(n=28, median 10.7 yrs)
SF3B1wt
(n=5, median 1.8 yrs)
p=0.001
3345791822283647
3344571421313750
Patients at risk
JAK2wt
(n=47, median 5.4 yrs; 
6-yr survival rate 32.2%)
p=0.019
JAK2V617F
(n=50, median 20.4 yrs; 
6-yr survival rate 67.4%)
a b
c d
Figure 3. Kaplan–Meier analysis for survival since diagnosis according to SF3B1 and JAK2V617F mutation status. SF3B1 in (a) total cohort, (b)
RARS-T, (c) RARS and (d) JAK2V617F in RARS-T.
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prognostic point of view, suggesting that RARS-T could be
considered as a unique entity.20 The results of our current study
showing the presence of both SF3B1 and JAK2V617F mutations in a
high proportion of RARS-T conﬁrm that RARS-T is a unique entity.
Indeed, RARS-T was associated with high rates of SF3B1 mutations
(86.5%) and JAK2V617F mutations while ET patients have a low
frequency of SF3B1 mutations, and in RARS, no JAK2V617F
mutations were detected.
A minority of RARS-T patients (13.5%) presented without SF3B1
mutations. This could be due to another mutation affecting
components of the RNA splicing machinery as mutations of SRSF2,
U2AF35 and ZRSR2 have already been described in 12.4, 7.3 and
3.1% of MDS, respectively,36 or due to mutations of proteins
associated with SF3B1 (SF3B4 and SF3B14).
These results are in line with our hypothesis that RARS-T is an
independent entity characterised by a particular molecular
combination associating mutations that give a myeloproliferative
advantage (JAK2V617F, MPLW515R/L or other unknown mutations)
and mutations of components of the splicing machinery
responsible for myelodysplastic features (SF3B1 in most cases,
and possibly SRSF2, U2AF35 or ZRSF2 in the remaining cases).
Conﬂicting results on the prognostic impact of SF3B1 mutations
in MDS have been reported as several studies noted a good
prognostic impact in MDS, whereas others hypothesised that SF3B1
mutations were associated with good-prognosis MDS subgroups
but lost their prognostic impact in RARS and in RCMD-RS.27
In our large cohort of RARS-T patients, SF3B1 mutations were
associated with female sex, higher ring sideroblast counts and a
longer overall survival than in SF3B1wt patients. In a multivariable
analysis, age 480 years at diagnosis, SF3B1wt as well as JAK2wt
were independent factors of a worse prognosis. Based on these
three independent parameters, a prognostic score for RARS-T
patients was created to deﬁne two risk groups: high risk when
there were two or three risk factors, low when there was only one
or no risk factor. Median survival was 1.6 vs 8.0 years in the high-
and low-risk group, respectively, underlying the relevance of such
score in RARS-T patients.
Exploring SF3B1 mutations in MDS associated with ring
sideroblasts is of interest from a prognostic point of view,
particularly as speciﬁc treatment will be available.37,38 Also,
allele-speciﬁc PCR have been designed, and these could be
useful for monitoring minimal residual disease in MDS.39
In summary, this study conﬁrms that RARS-T should be
considered an independent entity. In RARS-T patients, age o80
years at diagnosis, SF3B1 and JAK2 mutations are independent
factors for better survival and may be used to stratify patients.
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